News | December 07, 2010

Bioresorbable Stent Overinflates Without Cracking or Crazing

December 7, 2010 – A new bioresorbable stent scaffold can be overinflated by more than 25 percent without cracking or crazing. New data from Arterial Remodeling Technologies (ART) show that its bioresorbable polylactic acid (PLA) stent platform is designed to avoid malapposition.

With conventional stents a gap between the vessel and the stent can manifest. This "malapposition" of stent struts within the vessel has been shown to occur in conventional stent placements and is a significant risk factor in stent thrombosis. Additionally, data on other bioresorbable stents showed that when the struts have been overinflated to compensate for potential malapposition, they have cracked or crazed. This may lead to a life-threatening coronary event.

The company’s stent is designed to have a faster and smoother resorption; a non-crystalline polymer; better, homogeneous stress diffusion; and crack- and crazing-free expansion. In addition, the device is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility.

For more information: www.art-stent.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init